Treatment and prevention of malaria

Patent metadata

Field	Value
Publication number	US-12377138-B2
Application number	US-201917284617-A
Country	US
Kind code	B2
Filing date	Oct 10, 2019
Priority date	Oct 10, 2018
Publication date	Aug 5, 2025
Grant date	Aug 5, 2025

Abstract

There are provided antibodies and combination thereof, and other binding proteins against malarial antigens, as well as said antigens and vectors encoding the antibodies and antigens. The invention also provides the use of such compounds and combinations thereof in the prevention or treatment of malaria. In particular, synergistic combinations of non-neutralising antibodies directed towards an epitope on Reticulocyte-binding protein Homologue 5 (PfRH5) and neutralising antibodies directed towards Plasmodium merozoite antigens are provided.

First claim

The invention claimed is:

1. A non-neutralizing antibody, or binding fragment thereof, comprising:
(a) a heavy chain comprising a CDR1 sequence of SEQ ID NO: 11; a CDR2 sequence of SEQ ID NO: 12 and a CDR3 sequence of SEQ ID NO: 13, and a light chain comprising a CDR1 sequence of SEQ ID NO: 20; a CDR2 sequence of SEQ ID NO: 21 and a CDR3 sequence of SEQ ID NO: 22; or
(b) a heavy chain comprising a CDR1 sequence of SEQ ID NO: 14; a CDR2 sequence of SEQ ID NO: 15 and a CDR3 sequence of SEQ ID NO: 16, and a light chain comprising a CDR1 sequence of SEQ ID NO: 23; a CDR2 sequence of SEQ ID NO: 24 and a CDR3 sequence of SEQ ID NO: 25; or
(c) a heavy chain comprising a CDR1 sequence of SEQ ID NO: 17; a CDR2 sequence of SEQ ID NO: 18 and a CDR3 sequence of SEQ ID NO: 19, and a light chain comprising a CDR1 sequence of SEQ ID NO: 26; a CDR2 sequence of SEQ ID NO: 21 and a CDR3 sequence of SEQ ID NO: 27.

2. The non-neutralizing antibody, or binding fragment thereof of claim 1 , comprising:
(a) a heavy chain variable region sequence having at least 90% identity to SEQ ID NO: 47 and a light chain variable region sequence having at least 90% identity to SEQ ID NO: 48;
(b) a heavy chain variable region sequence having at least 90% identity to SEQ ID NO: 49 and a light chain variable region sequence having at least 90% identity to SEQ ID NO: 50; or
(c) a heavy chain variable region sequence having at least 90% identity to SEQ ID NO: 51 and a light chain variable region sequence having at least 90% identity to SEQ ID NO: 52.

3. The non-neutralizing antibody, or binding fragment thereof of claim 1 , wherein:
(d) the heavy chain variable region comprises a sequence having at least 95% identity to SEQ ID NO: 47 and the light chain variable region comprises a sequence having at least 95% identity to SEQ ID NO: 48;
(e) the heavy chain variable region comprises a sequence having at least 95% identity to SEQ ID NO: 49 and the light chain variable region comprises a sequence having at least 95% identity to SEQ ID NO: 50; or
(f) the heavy chain variable region comprises a sequence having at least 95% identity to SEQ ID NO: 51 and the light chain variable region comprises a sequence having at least 95% identity to SEQ ID NO: 52.

4. The non-neutralizing antibody, or binding fragment thereof of claim 1 , which is:
(a) a monoclonal or polyclonal antibody; or
(b) a Fab, F(ab′)2, Fv, scFv, Fd or dAb.

5. A bispecific dual variable domain molecule comprising a non-neutralizing antibody, or binding fragment thereof, of claim 1 and a neutralizing antibody, or binding fragment thereof, of claim 2 .

6. A composition comprising:
(a) one or more non-neutralizing antibody, or binding fragment thereof as defined in claim 1 ; and
(b) one or more neutralizing antibody, or binding fragment thereof, that specifically binds a Plasmodium merozoite antigen,
wherein the Plasmodium merozoite antigen is PfRH5 and the one or more neutralizing antibody, or binding fragment thereof, specifically binds an epitope within SEQ ID NO: 3 (RH5ΔN) or SEQ ID NO: 7 (RH5ΔNL), and the one or more neutralizing antibody, or binding fragment thereof, specifically binds an epitope corresponding to residues Gly201 to Lys219 and Lys327 to Gln342 of PfRH5 (SEQ ID NO: 1).

7. The composition of claim 6 , wherein the one or more neutralizing antibody, or binding fragment thereof; comprises:
(a) a heavy chain with a CDR1 sequence of SEQ ID NO: 54; a CDR2 sequence of SEQ ID NO: 55 and a CDR3 sequence of SEQ ID NO: 56, and a light chain with a CDR1 sequence of SEQ ID NO: 60; a CDR2 sequence of SEQ ID NO: 61 and a CDR3 sequence of SEQ ID NO: 62;
(b) a heavy chain with a CDR1 sequence of SEQ ID NO: 57; a CDR2 sequence of SEQ ID NO: 58 and a CDR3 sequence of SEQ ID NO: 59, and a light chain with a CDR1 sequence of SEQ ID NO: 63; a CDR2 sequence of SEQ ID NO: 64 and a CDR3 sequence of SEQ ID NO: 65;
wherein optionally the one or more neutralizing antibody, or binding fragment thereof; comprises:
(i) a heavy chain variable region sequence of SEQ ID NO: 81 and a light chain variable region sequence of SEQ ID NO: 82;
(ii) a heavy chain variable region sequence of SEQ ID NO: 83 and a light chain variable region sequence of SEQ ID NO: 84.

8. The composition of claim 6 , wherein each of the one or more non-neutralizing antibodies and the one or more neutralizing antibodies, or binding fragment thereof, is independently selected from:
(a) a monoclonal or polyclonal antibody; or
(b) a Fab, F(ab′)2, Fv, scFv, Fd or dAb.

Assignees

• Univ Oxford Innovation Ltd

Inventors

• Draper Simon
• Higgins Matthew
• Alanine Daniel G W

Classifications

• C12N15/115

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/31

  multispecific · CPC title